Step 1 topics → Psychiatry → Insomnia Disorder

Insomnia Disorder

Insomnia disorder is more than just trouble sleeping — it's a formal diagnosis with specific criteria that the DSM-5 lays out clearly, and USMLE Step 1 expects you to know them cold. The core idea: difficulty initiating or maintaining sleep (or early morning awakening) that occurs at least 3 nights per week, persists for at least 3 months, causes daytime impairment, and happens despite adequate opportunity for sleep. That last part matters — if someone can't sleep because they're working night shifts or their environment is chaotic, that's not insomnia disorder. The diagnosis requires ruling out inadequate sleep opportunity as the explanation.

The exam tests this in two main directions: recognizing a clinical vignette that meets (or fails to meet) criteria, and selecting appropriate management. On the criteria side, students often miss the frequency and duration thresholds — they'll diagnose insomnia disorder after two weeks of bad sleep, which is wrong. On the management side, the high-yield trap is defaulting to pharmacotherapy as first-line. That's the wrong instinct for Step 1. CBT-I is first-line for chronic insomnia disorder — full stop.

What makes this tricky is that the pharmacology of sleep aids is also testable, and students conflate 'knowing the drugs' with 'knowing when to use them.' You need both: CBT-I comes first, and if short-term pharmacotherapy is added, z-drugs (zolpidem, eszopiclone) and low-dose doxepin are preferred over benzodiazepines, which carry higher dependence risk. USMLE Step 1 loves testing the distinction between what's commonly done in practice versus what's evidence-based first-line.

From real student decks
41%have cards covering this topic
24%have mature cards

Common misconceptions

Common mistake
Gap: Unaware of the specific frequency (≥3 nights/week) and duration (≥3 months) criteria required to diagnose insomnia disorder
Insomnia disorder requires sleep difficulty at least 3 nights per week for at least 3 months with associated daytime impairment, despite adequate sleep opportunity.
The frequency and duration thresholds are non-negotiable for diagnosis: at least 3 nights per week and at least 3 months, with daytime impairment. A patient who has had two weeks of poor sleep — even severe poor sleep — does not meet criteria for insomnia disorder; that's acute insomnia. Also remember the 'despite adequate opportunity' clause: if someone isn't giving themselves enough time to sleep, the problem is behavioral, not a disorder.
Common mistake
Wrong: Pharmacotherapy (e.g., benzodiazepines or z-drugs) is the first-line treatment for chronic insomnia disorder.
Right: Cognitive behavioral therapy for insomnia (CBT-I) is the first-line treatment for chronic insomnia; pharmacotherapy is reserved for short-term adjunctive use.
Reaching for benzodiazepines or z-drugs first is the wrong move for chronic insomnia. CBT-I — which includes sleep restriction, stimulus control, sleep hygiene, and cognitive restructuring — has stronger long-term evidence than any pharmacologic agent and carries no dependence risk. Pharmacotherapy is appropriate short-term or as an adjunct, but on Step 1, if a question asks for first-line management of chronic insomnia disorder, CBT-I is the answer.
Common mistake
Gap: Unaware of the preferred short-term pharmacologic agents for insomnia and their relative risk profiles
Short-term pharmacologic options for insomnia include non-benzodiazepine GABA-A modulators (z-drugs: zolpidem, eszopiclone) and low-dose doxepin; benzodiazepines are used but carry higher dependence risk.
When pharmacotherapy is warranted (short-term or adjunctive), z-drugs like zolpidem and eszopiclone are preferred over benzodiazepines because they have a more favorable side effect and dependence profile — they're selective for GABA-A receptors containing the alpha-1 subunit. Low-dose doxepin (a sedating TCA) is also FDA-approved for insomnia, particularly for sleep maintenance issues. Benzodiazepines work but carry higher abuse and dependence liability, which makes them a lower-priority choice.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know the specific diagnostic criteria for insomnia disorder: sleep difficulty at least 3 nights per week, lasting at least 3 months, with daytime impairment, and despite adequate sleep opportunity.
  2. Identify the correct first-line treatment for chronic insomnia disorder — cognitive behavioral therapy for insomnia (CBT-I) — and recognize that pharmacotherapy is adjunctive and short-term, not first-line.
  3. Distinguish between short-term pharmacologic options for insomnia: z-drugs (zolpidem, eszopiclone) and low-dose doxepin are preferred over benzodiazepines due to lower dependence risk.

Can you avoid these mistakes?

A 34-year-old woman reports difficulty falling asleep at least 4 nights per week for the past 4 months. She feels fatigued at work and struggles to concentrate. She goes to bed at 11 PM and has to wake up at 6 AM. Does she meet criteria for insomnia disorder? What feature would rule out the diagnosis?
A patient is diagnosed with insomnia disorder. What is the first-line treatment, and when would you consider adding pharmacotherapy?
A physician prescribes a short-term sleep aid for a patient with insomnia disorder and wants to minimize dependence risk. She is choosing between lorazepam and zolpidem. Which is preferred and why?
A patient has had poor sleep for 10 days after a stressful life event. Her friend was diagnosed with insomnia disorder last year. What is the key reason this patient does NOT meet criteria for insomnia disorder, assuming her sleep difficulty is otherwise identical?

Related topics

Major Depressive Disorder (MDD) Persistent Depressive Disorder (Dysthymia) Bipolar I Disorder Bipolar II Disorder

See how your Anki deck covers this topic.

Upload your deck for a free audit →